Candel Therapeutics Inc. shares reached a 52-week high of $13.96 on Wednesday, closing within 1% of the peak at $13.93. The stock has surged 132.47% over the past 12 months, with a six-month gain of 153%, according to InvestingPro data.
The biotech’s market capitalization now stands at $1.06 billion, reflecting strong investor confidence amid progress in its late-stage oncology programs. Candel is developing aglatimagene besadenovec, an experimental therapy for metastatic non-squamous non-small cell lung cancer, which is being evaluated in the global Phase III AURORA trial.
The trial, involving approximately 150 sites worldwide, compares the experimental combination therapy against standard chemotherapy. Analysts at Freedom Broker raised their price target to $15, while H.C. Wainwright maintained a Buy rating with a $23 target. Stifel initiated coverage with a Buy rating and a $22 target, suggesting potential upside of 30-70% from current levels.
The company also appointed Mark Sims as chief commercial officer, effective July 2026, to lead commercial strategy for aglatimagene besadenovec in prostate cancer. Candel plans to submit a Biologics License Application for the therapy in late 2026, aligning with its regulatory timeline.
